RUA Life Sciences plc (RUA.L)
- Previous Close
11.88 - Open
11.33 - Bid 11.25 x --
- Ask 12.50 x --
- Day's Range
11.33 - 11.33 - 52 Week Range
9.89 - 15.70 - Volume
600 - Avg. Volume
113,148 - Market Cap (intraday)
7.447M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
11.88 - EPS (TTM)
0.01 - Earnings Date Jun 15, 2025 - Jun 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.00
RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops and commercializes bore polymer sealed grafts and soft tissue patches. The Structural Heart segment develops tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
rualifesciences.comRecent News: RUA.L
View MorePerformance Overview: RUA.L
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RUA.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RUA.L
View MoreValuation Measures
Market Cap
7.37M
Enterprise Value
4.77M
Trailing P/E
9.21
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.17
Price/Book (mrq)
0.94
Enterprise Value/Revenue
1.63
Enterprise Value/EBITDA
10.71
Financial Highlights
Profitability and Income Statement
Profit Margin
7.05%
Return on Assets (ttm)
0.75%
Return on Equity (ttm)
3.52%
Revenue (ttm)
2.92M
Net Income Avi to Common (ttm)
206k
Diluted EPS (ttm)
0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
3.78M
Total Debt/Equity (mrq)
14.72%
Levered Free Cash Flow (ttm)
-834.62k